Class Notes

Class Notes | Obituaries

Submit a Class Note or Obituary »

Showing class notes submitted in the last month by graduates in the 1970s

1973

UGRD Arts & Sciences '73
Weber, Walter

Walter G. Weber ’73 has been chosed by the California Dental Association (CDA) to be its new president for 2014–2015. Dr. Weber, who has been practicing general dentistry in Campbell, Calif., for more than 30 years and lives in Los Gatos, graduated from the Arthur A. Dugoni School of Dentistry and Santa Clara University, with a master's degree in business administration from Golden Gate University. He has been a CDA member for 33 years and succeeds past president, James D. Stephens, DDS.

During his recent installation speech at CDA's House of Delegates meeting, Dr. Weber emphasized the importance of CDA continually looking for ways to support members and the patients they serve in the profession's changing landscape, according to the association.
 
"Current trends in dentistry, including shrinking dental insurance benefits, pressures to reduce costs, and increasing costs of dental education, make it important for CDA to understand members' needs and develop strategies to help them succeed and best care for patients," Dr. Weber said. "Our members' success is critical for our organization to continue as the leaders in advocating for Californians' oral health."
 
Dr. Weber, past president of the Santa Clara County Dental Society, has served on the board of Tthe Dentists Insurance Company, CDA's Policy Development Council, and the Dental Benefits Task Force.
 
submitted Dec. 3, 2014 11:57A

1978

'78
Hubbard, John
John Hubbard '78 has been appointed CEO of BioClinica, a leading provider of specialty outsourced clinical trial services. He is also a member of the company's board of directors. A seasoned pharmaceutical executive, Dr. Hubbard, 58, will join the company from Pfizer Inc., where he has served as senior vice president and worldwide head of development operations. During his 30-year career, Dr. Hubbard has spearheaded pharmaceutical research and development initiatives for some of the industry's premier organizations.  At Pfizer, he was responsible for more than 450 Phase 1-4 clinical projects per year.  He also served on the taskforce that redesigned Pfizer's research and development organization.
 
Prior to Pfizer, Dr. Hubbard was group president of ICON plc's clinical research services business, the company's largest business division. During his tenure, ICON was named one of the country's fastest growing companies by FORTUNE.  Dr. Hubbard also has held management positions at PAREXEL International Corporation, Revlon Health Care Group and Hoechst Marion Roussel Pharmaceuticals (now owned by Sanofi).
 
 
Dr. Hubbard is a member of the Society of Clinical Pharmacology and Therapeutics, Drug Information Association and has served on its Special Interest Advisory Committee on Project Management.  He is a board certified diplomat in applied pharmacology and was elected as a fellow of the American College of Clinical Pharmacology (ACCP).  Dr. Hubbard has authored and co-authored articles and chapters on biopsychology, cardiovascular, clinical pharmacology and global drug development.  He received his bachelor's degree in biopsychology from the University of Santa Clara and a doctorate from the University of Tennessee.  Dr. Hubbard was a National Institute of Health postdoctoral fellow in cardiovascular and clinical pharmacology at the University of Texas Health Sciences Center.

 

submitted Nov. 21, 2014 6:21P

Search all notes/obituaries: